Medicsight Plc (AIM: MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce that Mr Troy Robinson (aged 34) has been appointed to the Board as Chief Financial Officer (CFO) and Company Secretary with immediate effect.

Troy joined Medicsight in February 2007 as Group Financial Controller after a successful career with IVAX pharmaceuticals and HP foods. During his tenure with Medicsight, Troy has played a pivotal role in both the Medicsight IPO and the subsequent global expansion of the finance function. Troy was appointed CFO in February 2009, as a non Board position, and has continued to contribute to The Company's success. Troy is an associate of the Chartered Institute of Management Accountants and holds a Bachelor of Arts degree from Manchester Metropolitan University.

Allan Rowley, CEO of Medicsight, commented “I am delighted to appoint Troy to the Board of Medicsight. He has made a significant contribution since joining the Company and I look forward to continuing to work with him as a member of the Medicsight Board.”

This announcement sets out the disclosures required pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies in respect of this appointment.

Troy Robinson holds interests in 300,000 Medicsight Plc Scheme J Share Options awarded on 15 May 2009. Scheme J will vest in equal one-sixths every six months for three years following the grant date.

Troy Robinson was a director of 115 Murray Road Management Company Limited between 2004 and 2005.

- ENDS -

For further information:

Media enquiries:

Notes to editors

Medicsight PLC is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight’s CAD software has been developed using one of the world’s largest and most population diverse databases of verified patient CT scan data. Medicsight’s ColonCAD^™ and LungCAD^™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the

image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome.

About Medicsight’s CAD software

Medicsight’s ColonCAD^™ and LungCAD^™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a ‘second read’, where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a ‘concurrent read’ where CAD findings are displayed during the user’s initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world’s foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company’s comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight’s products to be validated to the highest possible standards.